Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT)
FDMT Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
39.80%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
211.50%
FDMT Stock Analysis
FDMT
PE Ratio:
FDMT
PEG Ratio:
Not Available
FDMT
Forward EPS Growth (12 month):
0.00%
FDMT
PS Ratio:
5.6
FDMT
PSG Ratio:
0.1
FDMT
Forward Revenue Growth (12 month):
46.20%
FDMT Articles
No data was found